Current Report Filing (8-k)
11 October 2013 - 7:51AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 9, 2013
Vantage Health
(Exact name of registrant as specified in its
charter)
Nevada |
333-168930 |
93-0659770 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
105 West 55th Street, #3B
New York, NY |
10019 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: +27
728213420
_____________________________________________
(Former name or former address, if changed since
last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 1 – Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On October 9, 2013, Vantage Health (the "Company") executed
an Agreement of Conveyance, Transfer and Assignment of Subsidiary and Assumption of Obligations ("Agreement") for the
sale of the Company’s 51% interest in Moxisign (PTY) Ltd (“Moxisign”) with Lisa Ramakrishnan, an officer, director
and shareholder of the Company. Pursuant to the terms of the Agreement, Ms. Ramakrishnan agreed to assume all of the debts and
liabilities of Moxisign, totaling approximately $590,946. The assets of Moxisign are valued at approximately $95,248.
The foregoing description of the Agreement does not purport to be
complete and is qualified in its entirety by reference to the complete text of the Agreement filed as Exhibit 10.1 hereto and incorporated
herein by reference.
As a result of this transaction, we are no longer in the business
of becoming a pharmaceutical distributor with the specific intention of bidding on South African government health care contracts
and tenders. This line of business was sold under the Agreement. We are currently evaluating alternative business opportunities.
SECTION 9 – Financial
Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Vantage Health
/s/ Lisa Ramakrishnan
Lisa Ramakrishnan
President
Date: October 10, 2013
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024